<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04534894</url>
  </required_header>
  <id_info>
    <org_study_id>XH-20-015</org_study_id>
    <nct_id>NCT04534894</nct_id>
  </id_info>
  <brief_title>Single-center Clinical Study of Early Diagnosis of Diabetic Cardiomyopathy With FLIM</brief_title>
  <official_title>Single-center Clinical Study of Early Diagnosis of Diabetic Cardiomyopathy With Fluorescence Lifetime Imaging Microscopy (FLIM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic Cardiomyopathy (DCM) is disease of myocardial structure and function which is&#xD;
      independent of hypertension, coronary heart disease, heart valve abnormalities, and other&#xD;
      types of heart disease. DCM affects approximately 12% of diabetics and also appeared in some&#xD;
      patients with well-controlled blood glucose. There is no specific and effective diagnostic&#xD;
      method of DCM currently. Since it is well known that the dysfunction of myocardial metabolism&#xD;
      caused by hyperglycemia and insulin resistance induces DCM, the method of evaluation of the&#xD;
      metabolism will assist the diagnosis of DCM.&#xD;
&#xD;
      Nicotinamide adenine dinucleotide (phosphate) (NAD(P)H) is one of important coenzymes&#xD;
      involved in biological metabolism. Fluorescence lifetime microscopy (FLIM) can detect the&#xD;
      metabolic status based on the fluorescence characteristics of NAD(P)H. Previous studies have&#xD;
      reported that NAD(P)H fluorescence lifetime can be used to assess the metabolic status of&#xD;
      living cardiomyocytes cultured in vitro, and metabolism changes related to myocardial&#xD;
      infarction and heart failure in rats. the investigators detected the metabolic status by&#xD;
      label-free FLIM on the myocardial tissues and blood plasma in a rat model of type 2 diabetic&#xD;
      cardiomyopathy, and found FLIM could provide valuable information about the myocardial&#xD;
      metabolism by detecting the NAD(P)H fluorescence lifetime of blood plasma.&#xD;
&#xD;
      Recently, The investigators have explored the method of the FLIM in clinical study. The&#xD;
      investigators used FLIM to compare the NAD(P)H fluorescence lifetime of blood plasma in&#xD;
      healthy participants, type 2 diabetic patients with normal diastolic function and with&#xD;
      diastolic dysfunction. The results showed that the NAD(P)H fluorescence life parameter of a2&#xD;
      was lower in type 2 diabetic patients with diastolic dysfunction (30.5±2.7%) than in healthy&#xD;
      participants (41.5±4.8%) and type 2 diabetic patients with normal diastolic function&#xD;
      (37.8±3.7%). Therefore, The investigators propose FLIM can provide valuable information about&#xD;
      the myocardial metabolism, and it can be used as a non-invasive, label-free, and rapid&#xD;
      screening method of diagnosis of DCM.&#xD;
&#xD;
      In this study, the investigators will recruit 243 patients with type 2 diabetes and divide&#xD;
      them into two groups: normal diastolic function group (DM Group) and diastolic dysfunction&#xD;
      group (DCM Group), based on the symptoms, laboratory examination and echocardiographic&#xD;
      results. Then FLIM will be applied to detect the NAD(P)H fluorescence characteristics of&#xD;
      venous blood of all patients. After that, the correlation between the parameters of diastolic&#xD;
      function (E peak, E/E' ratio, left atrial volume, NT-proBNP) and the parameters of metabolism&#xD;
      status (NAD(P)H fluorescence life parameter of a2 and the ratio of bound state/free state&#xD;
      NAD(P)H) will be analyzed. This study will verify FLIM is helpful to diagnose DCM.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>fluorescence characteristics of NAD(P)H in venous blood by FLIM can assist early diagnosis of diabetic cardiomyopathy</measure>
    <time_frame>12 month</time_frame>
    <description>(NAD(P)H fluorescence life parameter of a2 (%) in venous blood is lower in DCM patients than DM patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fluorescence characteristics of NAD(P)H in venous blood by FLIM can assist early diagnosis of diabetic cardiomyopathy</measure>
    <time_frame>12 month</time_frame>
    <description>the ratio of bound state/free state NAD(P)H) (%) is lower in DCM patients than DM patients.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">243</enrollment>
  <condition>Diabetic Cardiomyopathies</condition>
  <arm_group>
    <arm_group_label>DM group and DCM group</arm_group_label>
    <description>DM group: type 2 diabetes with normal diastolic function DCM group: type 2 diabetes with diastolic dysfunction</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>fluorescence lifetime imaging microscopy</intervention_name>
    <description>collect 2mL of venous blood and use fluorescence lifetime imaging microscopy to exam NADH fluorescence characteristics of it</description>
    <arm_group_label>DM group and DCM group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        type 2 diabetes patients, divided into two groups, based on the diastolic funciton&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, aged 18-80 years old;&#xD;
&#xD;
          2. Echocardiography showed that the cardiac structure was normal and the left ventricular&#xD;
             ejection fraction was more than 50%;&#xD;
&#xD;
          3. patients with type 2 diabetes mellitus;&#xD;
&#xD;
          4. Body mass index (BMI) was 20-25 kg / m2 in male and 19-24 kg / m2 in female;&#xD;
&#xD;
          5. No other drugs except hypoglycemic drugs were taken in one month;&#xD;
&#xD;
          6. Sign informed consent form before entering this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with type 1 diabetes mellitus;&#xD;
&#xD;
          2. Patients with diabetic ketoacidosis in the past;&#xD;
&#xD;
          3. Patients with coronary heart disease or with myocardial ischemia indicated by ECG;&#xD;
&#xD;
          4. EGFR &lt; 60ml / min / 1.73m2 in recent one month;&#xD;
&#xD;
          5. Chronic liver disease, or the levels of alanine aminotransferase and glutamic&#xD;
             oxaloacetic transaminase were more than 3 times of the upper limit of the normal&#xD;
             before enrollment;&#xD;
&#xD;
          6. Abnormal thyroid function;&#xD;
&#xD;
          7. Abnormal tumor index;&#xD;
&#xD;
          8. Dyslipidemia;&#xD;
&#xD;
          9. Pregnant and lactating women;&#xD;
&#xD;
         10. Allergy to contrast media.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>guangyu chen, doctor</last_name>
    <role>Study Director</role>
    <affiliation>Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>kai guo, doctor</last_name>
    <phone>+86-21-25076143</phone>
    <email>guokai@xinhuamed.com.cn</email>
  </overall_contact>
  <results_reference>
    <citation>Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 1972 Nov 8;30(6):595-602.</citation>
    <PMID>4263660</PMID>
  </results_reference>
  <results_reference>
    <citation>Singh RM, Waqar T, Howarth FC, Adeghate E, Bidasee K, Singh J. Hyperglycemia-induced cardiac contractile dysfunction in the diabetic heart. Heart Fail Rev. 2018 Jan;23(1):37-54. doi: 10.1007/s10741-017-9663-y. Review.</citation>
    <PMID>29192360</PMID>
  </results_reference>
  <results_reference>
    <citation>De Jong KA, Lopaschuk GD. Complex Energy Metabolic Changes in Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction. Can J Cardiol. 2017 Jul;33(7):860-871. doi: 10.1016/j.cjca.2017.03.009. Epub 2017 Mar 19. Review.</citation>
    <PMID>28579160</PMID>
  </results_reference>
  <results_reference>
    <citation>Cook GA, Lavrentyev EN, Pham K, Park EA. Streptozotocin diabetes increases mRNA expression of ketogenic enzymes in the rat heart. Biochim Biophys Acta Gen Subj. 2017 Feb;1861(2):307-312. doi: 10.1016/j.bbagen.2016.11.012. Epub 2016 Nov 11.</citation>
    <PMID>27845231</PMID>
  </results_reference>
  <results_reference>
    <citation>Suhling K, Siegel J, Lanigan PM, Lévêque-Fort S, Webb SE, Phillips D, Davis DM, French PM. Time-resolved fluorescence anisotropy imaging applied to live cells. Opt Lett. 2004 Mar 15;29(6):584-6.</citation>
    <PMID>15035478</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang M, Tang F, Pan X, Yao L, Wang X, Jing Y, Ma J, Wang G, Mi L. Rapid diagnosis and intraoperative margin assessment of human lung cancer with fluorescence lifetime imaging microscopy. BBA Clin. 2017 Apr 27;8:7-13. doi: 10.1016/j.bbacli.2017.04.002. eCollection 2017 Dec.</citation>
    <PMID>28567338</PMID>
  </results_reference>
  <results_reference>
    <citation>Luo T, Lu Y, Liu S, Lin D, Qu J. Phasor-FLIM as a Screening Tool for the Differential Diagnosis of Actinic Keratosis, Bowen's Disease, and Basal Cell Carcinoma. Anal Chem. 2017 Aug 1;89(15):8104-8111. doi: 10.1021/acs.analchem.7b01681. Epub 2017 Jul 18.</citation>
    <PMID>28661125</PMID>
  </results_reference>
  <results_reference>
    <citation>Jing Y, Wang Y, Wang X, Song C, Ma J, Xie Y, Fei Y, Zhang Q, Mi L. Label-free imaging and spectroscopy for early detection of cervical cancer. J Biophotonics. 2018 May;11(5):e201700245. doi: 10.1002/jbio.201700245. Epub 2018 Jan 30.</citation>
    <PMID>29205885</PMID>
  </results_reference>
  <results_reference>
    <citation>Farwell DG, Meier JD, Park J, Sun Y, Coffman H, Poirier B, Phipps J, Tinling S, Enepekides DJ, Marcu L. Time-resolved fluorescence spectroscopy as a diagnostic technique of oral carcinoma: Validation in the hamster buccal pouch model. Arch Otolaryngol Head Neck Surg. 2010 Feb;136(2):126-33. doi: 10.1001/archoto.2009.216.</citation>
    <PMID>20157056</PMID>
  </results_reference>
  <results_reference>
    <citation>Lagarto J, Dyer BT, Talbot C, Sikkel MB, Peters NS, French PM, Lyon AR, Dunsby C. Application of time-resolved autofluorescence to label-free in vivo optical mapping of changes in tissue matrix and metabolism associated with myocardial infarction and heart failure. Biomed Opt Express. 2015 Jan 7;6(2):324-46. doi: 10.1364/BOE.6.000324. eCollection 2015 Feb 1.</citation>
    <PMID>25780727</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 19, 2020</study_first_submitted>
  <study_first_submitted_qc>August 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2020</study_first_posted>
  <last_update_submitted>August 27, 2020</last_update_submitted>
  <last_update_submitted_qc>August 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetic cardiomyopathy</keyword>
  <keyword>fluorescence lifetime imaging microscopy</keyword>
  <keyword>metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Diabetic Cardiomyopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

